Avalanche Biotechnologies Inc (ADVM)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)

800 SAGINAW DRIVE REDWOOD CITY, CA 94063

Avalanche Biotechnologies Inc. develops gene therapies for the treatment of ophthalmologic disorders. The Company creates therapeutic protein for treatments of eye disease. Avalanche operates in the United States.

Data as of 2021-04-11 07:45:01 -0400
Market Cap887.989 Million Shares Outstanding97.796 Million Avg 30-day Volume867.372 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE-5.39 Enterprise Value
Total Cash Current Debt Gross Profit
BETA1.79065 52-week High/Low26.98 / 8.98 Next Earnings Date2021-05-05 Price to Cash FLow (P/CF) -9999999.0
Data provided by IEX Cloud
View SEC Filings from ADVM instead.
Q4 2020 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 5 4 25.0% 0 (0.0%) 1 (0.06%) -100.0%
Funds Holding: 152 158 -3.8% 51 (3.06%) 56 (3.49%) -8.93%
13F shares: 94.267 Million 94.949 Million -0.72% 49.845 Million 50.206 Million -0.72%
% Ownership 96.7061 97.4064 -0.72% 51.1346 51.505 -0.72%
New Positions: 24 33 -27.27% 10 17 -41.18%
Increased Positions 52 66 -21.21% 17 25 -32.0%
Closed Positions 28 16 75.0% 15 10 50.0%
Reduced Positions 50 38 31.58% 18 11 63.64%
Total Calls 706.79 Thousand 661.965 Thousand 6.77% 390.3 Thousand 467.7 Thousand -16.55%
Total Puts 1.08 Million 414.556 Thousand 160.47% 686.3 Thousand 332.086 Thousand 106.66%
PUT/CALL Ratio 1.53 0.63 142.86% 1.76 0.71 147.89%
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding ADVM (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ADVM BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

40 Thousand total shares from 3 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

SVORONOS DAWN

  • Director
20,000 2021-03-31 3

MACHADO PATRICK

  • Director
88,182 2021-03-24 3

FISCHER LAURENT CEO AND DIRECTOR

  • Officer
  • Director
26,292 2021-03-24 6

TUCKSON REED VAUGHN

  • Director
45,000 2021-02-19 2

PATTERSON LEONE D PRESIDENT AND CFO

  • Officer
0 2021-02-16 4

OSBORNE AARON CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-16 1

SOPARKAR PETER CHIEF LEGAL OFFICER

  • Officer
0 2021-02-16 2

THEDINGA ANGELA CHIEF TECHNOLOGY OFFICER

  • Officer
0 2021-02-16 1

WOIWODE THOMAS

  • Director
18,822 2020-12-14 2

GASMI MEHDI

  • Director
274,442 2020-07-20 7

CARTER ERIC G

  • Director
0 2020-06-23 1

HEMRAJANI REKHA

  • Director
0 2020-06-23 1

SCOPA JAMES PAUL

  • Director
0 2020-06-23 2

LUPHER, JR. MARK L.

  • Director
0 2020-06-23 1

WHITCUP SCOTT M

  • Director
0 2020-06-23 1

LEUNG THOMAS CHIEF FINANCIAL OFFICER

  • Officer
0 2020-02-20 0

FINER MITCHELL H.

  • Director
0 2019-07-31 0

SPIVEY RICHARD N.

  • Director
0 2019-07-31 0

CHENG JENNIFER C. GENERAL COUNSEL

  • Officer
0 2019-02-14 0

CLEVELAND PAUL B

  • Director
0 2018-05-31 0

SALZMAN AMBER PRESIDENT AND CEO

  • Officer
  • Director
0 2018-02-15 0

COUNTOURIOTIS ATHENA SVP, CHIEF MEDICAL OFFICER

  • Officer
0 2018-02-15 0

SCHWARTZ STEVEN DANIEL

  • Director
398,991 2017-06-12 0

BARONE SAMUEL B. SVP, CLINICAL DEVELOPMENT

  • Officer
172,335 2017-02-09 0

RUSSO CARLO EVP AND CHIEF MEDICAL OFFICER

  • Officer
0 2016-05-11 0

VERSANT VENTURES IV, LLC

VERSANT VENTURE CAPITAL IV, L.P.

VERSANT IV LUXCO S.A R.L.

VERSANT CAPITAL IV (SWITZERLAND) GMBH

  • 10% Owner
7,003,892 2016-05-11 0

WACHTER PAUL

  • Director
69,112 2016-02-29 0

BLUMENKRANZ MARK S.

  • Director
562,915 2016-02-12 0

MCLAUGHLIN JOHN PETER

  • Director
36,893 2016-02-12 0

RUBIO ROMAN G. SVP, TRANSLATIONAL MEDICINE

  • Officer
165,650 2016-02-12 0

BRAUN SHIRLEY VP, HUMAN RESOURCES

  • Officer
161,140 2016-02-12 0

SWARTZBURG MICHAEL PRINCIPAL ACCOUNTING OFFICER

  • Officer
82,113 2016-02-12 0

BAIN LINDA CHIEF FINANCIAL OFFICER

  • Officer
41,930 2015-08-21 0

HULL HANS CHIEF EXECUTIVE OFFICER

  • Officer
137,210 2015-08-21 0

CHALBERG THOMAS W. CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
1,099,401 2015-06-10 0

GUERIN JOHN PATRICK ET AL

  • Director
  • 10% Owner
200,000 2015-05-27 0

ZYGTECH, LLC

  • 10% Owner
No longer subject to file 2015-04-13 0

REGENERON PHARMACEUTICALS INC

  • 10% Owner
No longer subject to file 2014-08-05 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.

DEERFIELD MGMT III, L.P.

DEERFIELD MANAGEMENT CO

DEERFIELD PRIVATE DESIGN FUND III, L.P.

DEERFIELD PARTNERS, LP

DEERFIELD INTERNATIONAL MASTER FUND, L.P.

  • 10% Owner
  • POSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUPPOSSIBLE MEMBERS OF 10% GROUP
No longer subject to file 2014-08-05 0

VENROCK ASSOCIATES VI, L.P.

VENROCK PARTNERS VI, L.P.

VENROCK MANAGEMENT VI, LLC

VENROCK PARTNERS MANAGEMENT VI, LLC

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VHCP CO-INVESTMENT HOLDINGS, LLC

VHCP MANAGEMENT, LLC

HOVE ANDERS D

KOH BONG Y

  • 10% Owner
2,365,471 2014-08-05 0

VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P.

VHCP CO-INVESTMENT HOLDINGS II, LLC

VHCP MANAGEMENT II, LLC

  • 10% Owner
2,365,471 2014-08-05 0

VENROCK ASSOCIATES VI, L.P.

VENROCK PARTNERS VI, L.P.

VENROCK MANAGEMENT VI, LLC

VENROCK PARTNERS MANAGEMENT VI, LLC

VENROCK HEALTHCARE CAPITAL PARTNERS LP

VHCP CO-INVESTMENT HOLDINGS, LLC

VHCP MANAGEMENT, LLC

ROBERTS BRYAN E

HOVE ANDERS D

  • 10% Owner
0 2014-07-30 0

FLYNN JAMES E

DEERFIELD MGMT L.P.

DEERFIELD SPECIAL SITUATIONS INTERNATIONAL MASTER FUND, L.P.

DEERFIELD SPECIAL SITUATIONS FUND, L.P.

DEERFIELD MGMT III, L.P.

DEERFIELD PRIVATE DESIGN FUND III, L.P.

  • 10% Owner
  • POSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUPPOSSIBLE MEMBER OF 10% GROUP
0 2014-07-30 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

SVORONOS DAWN - Director

2021-04-01 20:21:42 -0400 2021-03-31 P 20,000 $10.02 a 20,000 direct -6.3447 -14.1098 0.0 1 -14.1098 6

FISCHER LAURENT - Director - Officer CEO AND DIRECTOR

2021-03-24 19:47:46 -0400 2021-03-24 P 10,000 $9.88 a 26,292 direct -2.6445 -1.2733 0.0 1 -7.6396 3

MACHADO PATRICK - Director

2021-03-24 19:46:53 -0400 2021-03-24 P 10,000 $9.92 a 88,182 direct -2.6445 -1.2733 0.0 1 -7.6396 3

TUCKSON REED VAUGHN - Director

2021-02-23 19:13:36 -0500 2021-02-19 A 45,000 a 45,000 direct

PATTERSON LEONE D - Officer PRESIDENT AND CFO

2021-02-18 21:03:54 -0500 2021-02-16 A 240,000 a 240,000 direct

OSBORNE AARON - Officer CHIEF MEDICAL OFFICER

2021-02-18 21:04:39 -0500 2021-02-16 A 150,000 a 150,000 direct

THEDINGA ANGELA - Officer CHIEF TECHNOLOGY OFFICER

2021-02-18 21:06:03 -0500 2021-02-16 A 250,000 a 250,000 direct

FISCHER LAURENT - Director - Officer CEO AND DIRECTOR

2021-02-18 21:03:02 -0500 2021-02-16 A 680,000 a 680,000 direct

SOPARKAR PETER - Officer CHIEF LEGAL OFFICER

2021-02-18 21:05:24 -0500 2021-02-16 A 140,000 a 140,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 22:15:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 21:45:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 21:15:02 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 20:45:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 20:15:04 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 19:45:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 19:15:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 18:45:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 18:15:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 17:45:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 17:15:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 16:45:02 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 16:15:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 15:45:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 15:15:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 14:45:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 14:15:02 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 13:45:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 13:15:03 UTC -0.3048 0.3648 800000
ADVERUM BIOTECHNOLOGIES INC ADVM 2021-04-16 12:45:02 UTC -0.3048 0.3648 800000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
Trust for Professional Managers- Convergence Market Neutral Fund ADVM -5066.0 shares, $-61805.2 2020-08-31 N-PORT
PACE SELECT ADVISORS TRUST- PACE Alternative Strategies Investments ADVM -21840.0 shares, $-269287.2 2021-01-31 N-PORT
INVESTMENT MANAGERS SERIES TRUST- 361 Global Long/Short Equity Fund ADVM -206285.0 shares, $-2543494.05 2021-01-31 N-PORT
Columbia Funds Series Trust I- Multi-Manager Directional Alternative Strategies Fund ADVM -25066.0 shares, $-309063.78 2021-01-31 N-PORT

Elevate your investments